BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms


Small molecule inhibition of the BET family of proteins, which bind acetylated lysines within histones, has been shown to have a marked therapeutic benefit in pre-clinical models of mixed lineage leukemia (MLL) fusion protein-driven leukemias. Here, we report that I-BET151, a highly specific BET family bromodomain inhibitor, leads to growth inhibition in a… (More)
DOI: 10.1038/leu.2013.234


7 Figures and Tables

Cite this paper

@article{Wyspianska2014BETPI, title={BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms}, author={Beata Wyspianska and A. J. Bannister and Italo Marco Barbieri and Jyoti Nangalia and Alan Godfrey and Fernando J. Calero-Nieto and S. Robson and Inma Rioja and J Li and Meike Wiese and Elvira Cannizzaro and Mark A Dawson and Brian Jp Huntly and Rab K Prinjha and A. R. Green and Berthold G{\"o}ttgens and Tony Kouzarides}, journal={Leukemia}, year={2014}, volume={28}, pages={88-97} }